Johnson & Johnson subsidiary Janssen has launched an interactive educational website about diabetes for European healthcare professionals.
The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.
Galena Biopharma has purchased rights to a treatment for breakthrough cancer pain from a Swedish drug maker, Galena said Monday.
The Food and Drug Administration will review an acid-reflux drug made by Eisai for use in children, the drug maker said.
A drug maker that specializes in pain medications started the third late-stage trial of a drug for treating pain in patients who have undergone certain surgeries.
Forest Labs has bought rights to a drug used for high blood pressure that it had marketed with a Johnson & Johnson subsidiary, thus eliminating the need to pay future royalties.
Forest Labs has filed suit against Glenmark Generics and several other companies, alleging that they infringed on its patent for a drug to treat hypertension by seeking regulatory approval for generic versions.
Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.
Shire has acquired U.S. rights to a drug used to treat chronic constipation in women from Johnson & Johnson, the company said Tuesday.
A generic version of a popular pneumonia treatment has entered the market from Hi-Tech Pharmacal.
A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.
Johnson & Johnson is recalling 40,000 bottles of a drug used to treat schizophrenia due to consumer reports of the drug having a strange odor, the company said Friday.
The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating schizophrenia in adolescents.
Generic drug maker Watson Pharmaceuticals will distribute an authorized generic version of a drug used...
Two subsidiaries of Johnson & Johnson will pay more than $81 million to the federal...